N1/N2-lactam acetyl-CoA carboxylase inhibitors
    9.
    发明授权
    N1/N2-lactam acetyl-CoA carboxylase inhibitors 有权
    N1 / N2-内酰胺乙酰辅酶A羧化酶抑制剂

    公开(公告)号:US08993586B2

    公开(公告)日:2015-03-31

    申请号:US14497396

    申请日:2014-09-26

    Applicant: Pfizer Inc.

    CPC classification number: C07D471/20 C07D519/00

    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

    Abstract translation: 本发明提供式(I)化合物或其药学上可接受的盐; 其中G为R 1,R 2和R 3如本文所述; 其药物组合物; 以及其用于治疗通过抑制动物体内的乙酰辅酶A羧化酶调节的疾病,病症或病症的用途。

    N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS
    10.
    发明申请
    N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS 有权
    N1 / N2-LACTAM乙酰辅酶C羧酸酶抑制剂

    公开(公告)号:US20150025098A1

    公开(公告)日:2015-01-22

    申请号:US14497396

    申请日:2014-09-26

    Applicant: PFIZER INC.

    CPC classification number: C07D471/20 C07D519/00

    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

    Abstract translation: 本发明提供式(I)化合物或其药学上可接受的盐; 其中G为R 1,R 2和R 3如本文所述; 其药物组合物; 以及其用于治疗通过抑制动物体内的乙酰辅酶A羧化酶调节的疾病,病症或病症的用途。

Patent Agency Ranking